View Future GrowthVitalist 過去の業績過去 基準チェック /06Vitalistは25.8%の年平均成長率で業績を伸ばしているが、Consumer Durables業界はdecliningで1.9%毎年増加している。売上は減少しており、年平均17.8%の割合である。主要情報25.82%収益成長率42.97%EPS成長率Consumer Durables 業界の成長24.52%収益成長率-17.77%株主資本利益率n/aネット・マージン-83.82%前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Jul 20Vitalist Inc., Annual General Meeting, Sep 29, 2026Vitalist Inc., Annual General Meeting, Sep 29, 2026. Location: at 2100 livingston place, 222 3 ave sw, ab t2p 0b4, calgary Canadaお知らせ • Jul 02Vitalist Inc. Announces Resignation of Nick Padula from Chief Revenue Officer RoleVitalist Inc. announced that Chief Revenue Officer Nick Padula would be concluding his role with the Company following his support of the post-acquisition integration and commercial transition of Somatix Inc. Nick and the Vitalist team were working closely together to ensure a seamless hand-off of responsibilities over the coming weeks. In connection with Mr. Padula's departure, Vitalist's commercial and sales operations would report directly to CEO Kalvie Legat with health and wellness business development continuing to report through Dr. Charles Herman who serves as CSO of Vitalist and CEO of Vitalist subsidiary Somatix Inc.お知らせ • May 01Vitalist Inc. (TSXV:VITA) acquired Somatix, Inc. for CAD 6.7 million.Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million on March 30, 2026. The consideration consists of 15.58 million common equity of Vitalist Inc. to be issued for common equity of Somatix, Inc. Following the Closing, Somatix, Inc's Stockholders will hold approximately 23.4% of Vitalist's issued and outstanding common shares. Upon closing of the Transaction, Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix and Nick Padula joins the executive team as President of Somatix and Chief Revenue Officer of both Somatix and Vitalist. For the period ending December 31, 2025, Somatix, Inc. reported total revenue of CAD 0.15 million ($0.11 million) and net loss of CAD 4.25 million ($3.05 million). As of December 31, 2025, Somatix, Inc. reported total assets of CAD 3.24 million ($2.33 million). Completion remains subject to the final approval of TSX Venture Exchange and the satisfaction of customary closing conditions. Kingswood Capital Partners, LLC acted as financial advisor for Somatix, Inc. Kier Advisory Services acted as financial advisor for Vitalist Inc. Kingswood Capital Partners, LLC will receive a finder’s fee consisting of CAD 0.14 million ($0.1 million) in cash and Vitalist common shares equivalent to a value of CAD 0.06 million ($0.05 million), conditional upon the Closing. Vitalist Inc. (TSXV:VITA) completed the acquisition of Somatix, Inc. on April 30, 2026. Under the terms of the transaction, Vitalist issued 15,581,854 of its common shares in exchange for 100% of the common stock of Somatix. Following closing, the former Somatix stockholders held approximately 23.24% of the issued and outstanding common shares of Vitalist. Kingswood Capital Partners, LLC was paid a financial advisory fee consisting of CAD 0.13 million ($0.1 million) in cash and 87,812 common shares of Vitalist issued at a price of CAD 0.71 per share.お知らせ • Apr 02Vitalist Inc. Announces Executive AppointmentsVitalist Inc. announced that Dr. Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix. Dr. Herman is a distinguished surgeon and healthcare executive with over 20 years of experience in clinical practice and medical technology innovation. In addition to his leadership at Somatix, Dr. Herman serves as a Portfolio Manager at Forefront Analytics, where he applies quantitative insights to healthcare investments. He previously served as Chief Medical Executive for multiple healthcare systems and has held executive leadership and faculty positions at major medical institutions and universities. Dr. Herman holds an M.D. from Albany Medical College in New York and an M.B.A. from the Wharton School of the University of Pennsylvania, where he is a Palmer Scholar. Nick Padula joins the executive team as Chief Revenue Officer of Vitalist. Mr. Padula is a senior executive with over 30 years of experience driving market share growth and operational excellence across major healthcare and medical technology firms. He has previously held senior leadership roles at Philips Healthcare, GE Healthcare, and Health Recovery Solutions, where he led large-scale commercial organizations and successfully integrated complex global acquisitions.お知らせ • Apr 01Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million.Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million on March 30, 2026. The consideration consists of 15.58 million common equity of Vitalist Inc. to be issued for common equity of Somatix, Inc. Following the Closing, Somatix, Inc's Stockholders will hold approximately 23.4% of Vitalist's issued and outstanding common shares. Upon closing of the Transaction, Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix and Nick Padula joins the executive team as President of Somatix and Chief Revenue Officer of both Somatix and Vitalist. For the period ending December 31, 2025, Somatix, Inc. reported total revenue of CAD 0.15 million ($0.11 million) and net loss of CAD 4.25 million ($3.05 million). As of December 31, 2025, Somatix, Inc. reported total assets of CAD 3.24 million ($2.33 million). Completion remains subject to the final approval of TSX Venture Exchange and the satisfaction of customary closing conditions. Kingswood Capital Partners, LLC acted as financial advisor for Somatix, Inc. Kier Advisory Services acted as financial advisor for Vitalist Inc. Kingswood Capital Partners, LLC will receive a finder’s fee consisting of CAD 0.14 million ($0.1 million) in cash and Vitalist common shares equivalent to a value of CAD 0.06 million ($0.05 million), conditional upon the Closing.お知らせ • Dec 02Vitalist Inc. and MicroEJ Announce New Reebok Smartwatch Powered by VitalOSVitalist Inc. and MicroEJ announced the launch of the first Reebok smartwatch powered by VitalOS, marking the public debut of an operating system designed to support consumer brands entering the wearable market. With Reebok as the first commercial implementation, VitalOS illustrates the platform's capabilities and showcases its capabilities, providing an alternative approach to developing wearables without reliance on proprietary ecosystems. VitalOS is built on MicroEJ's proven virtualization technology, MicroEJ VEE, and its wearable solution, VEE Wear -- part of a platform that already powers more than 400 million connected devices worldwide. Together, the companies have created a foundation that streamlines the cost, speed, and scale of wearable development: Low-power architecture designed to support extended battery performance; 6-9 month development cycles; Customization options for brand-specific experiences; Hardware-agnostic scalability.収支内訳Vitalist の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:VTLS.F 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費31 Dec 255-44030 Sep 256-34030 Jun 255-44031 Mar 255-43031 Dec 245-34030 Sep 244-44030 Jun 242-54031 Mar 24244031 Dec 233-125030 Sep 234-176030 Jun 236-177031 Mar 238-288131 Dec 2210-148130 Sep 229-108130 Jun 229-108131 Mar 227-108031 Dec 215-107030 Sep 217-127030 Jun 218-148031 Mar 219-148031 Dec 2010-1510030 Sep 209-1410130 Jun 208-119031 Mar 207-109031 Mar 193-34031 Mar 181-11031 Mar 172010質の高い収益: VTLS.Fは現在利益が出ていません。利益率の向上: VTLS.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: VTLS.Fは利益を出していないが、過去 5 年間で年間25.8%の割合で損失を削減してきた。成長の加速: VTLS.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: VTLS.Fは利益が出ていないため、過去 1 年間の収益成長をConsumer Durables業界 ( -15.2% ) と比較することは困難です。株主資本利益率高いROE: VTLS.Fの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YConsumer-durables 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 16:12終値2026/07/23 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vitalist Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 20Vitalist Inc., Annual General Meeting, Sep 29, 2026Vitalist Inc., Annual General Meeting, Sep 29, 2026. Location: at 2100 livingston place, 222 3 ave sw, ab t2p 0b4, calgary Canada
お知らせ • Jul 02Vitalist Inc. Announces Resignation of Nick Padula from Chief Revenue Officer RoleVitalist Inc. announced that Chief Revenue Officer Nick Padula would be concluding his role with the Company following his support of the post-acquisition integration and commercial transition of Somatix Inc. Nick and the Vitalist team were working closely together to ensure a seamless hand-off of responsibilities over the coming weeks. In connection with Mr. Padula's departure, Vitalist's commercial and sales operations would report directly to CEO Kalvie Legat with health and wellness business development continuing to report through Dr. Charles Herman who serves as CSO of Vitalist and CEO of Vitalist subsidiary Somatix Inc.
お知らせ • May 01Vitalist Inc. (TSXV:VITA) acquired Somatix, Inc. for CAD 6.7 million.Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million on March 30, 2026. The consideration consists of 15.58 million common equity of Vitalist Inc. to be issued for common equity of Somatix, Inc. Following the Closing, Somatix, Inc's Stockholders will hold approximately 23.4% of Vitalist's issued and outstanding common shares. Upon closing of the Transaction, Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix and Nick Padula joins the executive team as President of Somatix and Chief Revenue Officer of both Somatix and Vitalist. For the period ending December 31, 2025, Somatix, Inc. reported total revenue of CAD 0.15 million ($0.11 million) and net loss of CAD 4.25 million ($3.05 million). As of December 31, 2025, Somatix, Inc. reported total assets of CAD 3.24 million ($2.33 million). Completion remains subject to the final approval of TSX Venture Exchange and the satisfaction of customary closing conditions. Kingswood Capital Partners, LLC acted as financial advisor for Somatix, Inc. Kier Advisory Services acted as financial advisor for Vitalist Inc. Kingswood Capital Partners, LLC will receive a finder’s fee consisting of CAD 0.14 million ($0.1 million) in cash and Vitalist common shares equivalent to a value of CAD 0.06 million ($0.05 million), conditional upon the Closing. Vitalist Inc. (TSXV:VITA) completed the acquisition of Somatix, Inc. on April 30, 2026. Under the terms of the transaction, Vitalist issued 15,581,854 of its common shares in exchange for 100% of the common stock of Somatix. Following closing, the former Somatix stockholders held approximately 23.24% of the issued and outstanding common shares of Vitalist. Kingswood Capital Partners, LLC was paid a financial advisory fee consisting of CAD 0.13 million ($0.1 million) in cash and 87,812 common shares of Vitalist issued at a price of CAD 0.71 per share.
お知らせ • Apr 02Vitalist Inc. Announces Executive AppointmentsVitalist Inc. announced that Dr. Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix. Dr. Herman is a distinguished surgeon and healthcare executive with over 20 years of experience in clinical practice and medical technology innovation. In addition to his leadership at Somatix, Dr. Herman serves as a Portfolio Manager at Forefront Analytics, where he applies quantitative insights to healthcare investments. He previously served as Chief Medical Executive for multiple healthcare systems and has held executive leadership and faculty positions at major medical institutions and universities. Dr. Herman holds an M.D. from Albany Medical College in New York and an M.B.A. from the Wharton School of the University of Pennsylvania, where he is a Palmer Scholar. Nick Padula joins the executive team as Chief Revenue Officer of Vitalist. Mr. Padula is a senior executive with over 30 years of experience driving market share growth and operational excellence across major healthcare and medical technology firms. He has previously held senior leadership roles at Philips Healthcare, GE Healthcare, and Health Recovery Solutions, where he led large-scale commercial organizations and successfully integrated complex global acquisitions.
お知らせ • Apr 01Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million.Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million on March 30, 2026. The consideration consists of 15.58 million common equity of Vitalist Inc. to be issued for common equity of Somatix, Inc. Following the Closing, Somatix, Inc's Stockholders will hold approximately 23.4% of Vitalist's issued and outstanding common shares. Upon closing of the Transaction, Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix and Nick Padula joins the executive team as President of Somatix and Chief Revenue Officer of both Somatix and Vitalist. For the period ending December 31, 2025, Somatix, Inc. reported total revenue of CAD 0.15 million ($0.11 million) and net loss of CAD 4.25 million ($3.05 million). As of December 31, 2025, Somatix, Inc. reported total assets of CAD 3.24 million ($2.33 million). Completion remains subject to the final approval of TSX Venture Exchange and the satisfaction of customary closing conditions. Kingswood Capital Partners, LLC acted as financial advisor for Somatix, Inc. Kier Advisory Services acted as financial advisor for Vitalist Inc. Kingswood Capital Partners, LLC will receive a finder’s fee consisting of CAD 0.14 million ($0.1 million) in cash and Vitalist common shares equivalent to a value of CAD 0.06 million ($0.05 million), conditional upon the Closing.
お知らせ • Dec 02Vitalist Inc. and MicroEJ Announce New Reebok Smartwatch Powered by VitalOSVitalist Inc. and MicroEJ announced the launch of the first Reebok smartwatch powered by VitalOS, marking the public debut of an operating system designed to support consumer brands entering the wearable market. With Reebok as the first commercial implementation, VitalOS illustrates the platform's capabilities and showcases its capabilities, providing an alternative approach to developing wearables without reliance on proprietary ecosystems. VitalOS is built on MicroEJ's proven virtualization technology, MicroEJ VEE, and its wearable solution, VEE Wear -- part of a platform that already powers more than 400 million connected devices worldwide. Together, the companies have created a foundation that streamlines the cost, speed, and scale of wearable development: Low-power architecture designed to support extended battery performance; 6-9 month development cycles; Customization options for brand-specific experiences; Hardware-agnostic scalability.